CoolSculpting® Announces Only FDA-Cleared Non-Invasive Treatment for Upper Arm Fat
January 26 2017 - 9:00AM
Over 14 Million People in U.S. Cite Upper
Arm Fat as Troubling
ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology
company focused on developing and commercializing products
utilizing its proprietary controlled-cooling technology, today
announced that CoolSculpting® is FDA-cleared for upper arms, making
it the only non-invasive fat removal technology cleared by the FDA
to address this body area.
“There are 29 million people in the U.S.
interested in CoolSculpting, with more than 14 million expressing
concern about unwanted arm fat, making arms the third most popular
area for consideration of non-invasive fat reduction,” said Mark
Foley, President and Chief Executive Officer of ZELTIQ. "As
demonstrated with our recent FDA clearance, we are committed to
investing in R&D and clinical research to provide consumers
with solutions that they desire most. CoolSculpting’s ability to
successfully treat upper arm fat is a testament to our technology’s
efficacy and versatility, as well as our position as the market
leader in non-invasive fat reduction.”
The company also announced that it will be
launching the CoolAdvantage Petite applicator for the CoolSculpting
system in order to optimize the performance of CoolSculpting in the
upper arms, with full commercial release targeted for the middle
part of the year. The newest member of the CoolAdvantage
family of applicators, the CoolAdvantage Petite treatment comes
with two interchangeable contours designed to uniquely treat the
upper arm area in just 35 minutes.
"My patients have been asking for a non-invasive
solution for their unwanted arm fat so I am thrilled to be able to
offer them a proven solution that is safe and effective," said
Grant Stevens, MD, FACS, Founder and Medical Director of Marina
Plastic Surgery and Medical Director of Body by
OrangeTwist. "We anticipate a lot of interest from our
patients now that there is an FDA-cleared solution to treat this
challenging area."
CoolSculpting is a safe and effective treatment
for non-invasive fat reduction with unmatched clinical
evidence. With more than 70 peer-reviewed clinical papers and
abstracts and over 3.5 million treatments performed to date in over
80 countries around the world, CoolSculpting is the clear market
leader in non-invasive fat reduction. CoolSculpting is FDA-cleared
for the treatment of fat bulges in the submental area, thigh,
abdomen, flank, bra and back fat area, underneath the buttocks and
now, the upper arm.
CoolSculpting is available through an elite
network of CoolSculpting Centers worldwide. Dermatologists, plastic
surgeons and leading aesthetic specialists that offer CoolSculpting
can be found at www.coolsculpting.com.
About the CoolSculpting®
ProcedureCoolSculpting is a non-surgical, clinically
proven procedure that selectively reduces unwanted fat using a
patented cooling technology. Cleared by the FDA, CoolSculpting
works by gently cooling targeted fat cells in the body to induce a
natural, controlled elimination of fat cells without affecting
surrounding tissue, and the treated fat cells are gone for
good. Millions of CoolSculpting treatments have been
performed by more than 5,700 CoolSculpting systems in over 80
countries. Market research indicates up to a 95 percent customer
satisfaction rate with the CoolSculpting procedure. CoolSculpting
is available through an elite network of CoolSculpting Centers
worldwide. Dermatologists, plastic surgeons and leading aesthetic
specialists that offer CoolSculpting can be found at
www.coolsculpting.com.
Be sure to follow CoolSculpting
on Facebook, Twitter, Pinterest and YouTube.
About ZELTIQ® Aesthetics,
Inc.ZELTIQ. is a medical technology company focused on
developing and commercializing products utilizing its proprietary
controlled-cooling technology platform. ZELTIQ’s first
commercial product, the CoolSculpting system, is designed to
selectively reduce stubborn fat bulges. CoolSculpting is
based on the scientific principle that fat cells are more sensitive
to cold than the overlying skin and surrounding tissues. It
utilizes patented technology of precisely controlled cooling to
reduce the temperature of fat cells in the treated area, which is
intended to cause fat cell elimination through a natural biological
process known as apoptosis. ZELTIQ developed CoolSculpting to
safely, noticeably, and measurably reduce the fat layer.
Forward-Looking StatementsThe
statements made in this press release
regarding ZELTIQ's targeted mid-2017 full commercial
release of the CoolAdvantage Petite applicator, and other
statements relating to future expectations or events are
forward-looking statements. The words “target,” "anticipate,"
"expect," "estimate," "planned," and similar words that denote
future events or results identify these forward-looking statements.
You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases,
beyond ZELTIQ's control and that could materially
affect ZELTIQ's actual business operations. Factors that
could materially affect ZELTIQ's business operations
include, but are not limited to slower than expected product
development as well as those other risks and uncertainties set
forth in ZELTIQ's Quarterly Report on Form 10-Q for the
third quarter ended September 30, 2016, filed with
the SEC on November 9, 2016. These forward-looking
statements speak only as of the date of this press
release. ZELTIQ expressly disclaims any obligation to
update information contained in these forward-looking statements
whether as a result of new information, future events or
otherwise.
MEDIA CONTACT:
Jill Knepper
Ketchum for ZELTIQ
310-437-2517
INVESTOR RELATIONS:
Taylor Harris
ZELTIQ, Senior Vice President and CFO
925-474-2500
Nick Laudico
The Ruth Group for ZELTIQ
646-536-7030
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From May 2024 to Jun 2024
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2023 to Jun 2024